Business
Alpha Cognition is focused on commercial manufacturing and sales of ZUNVEYL, its oral tablet therapy for mild-to-moderate dementia of the Alzheimer's type.
Alpha Cognition launched ZUNVEYL, but revenue fell hard while losses and cash burn deepened.
The read at a glance✓ Audited against SEC data
- Business mix — ZUNVEYL for Alzheimer's diseaseNote
- Revenue — Revenue -89.8% to $10.2MWatch
- Profitability — Net loss widened to $20.7MWatch
- Cash burn — Free cash flow was -$20.7MWatch
- Balance sheet — Equity +59.9% to $62.5MOK
- Insiders — 23 buys / 1 sell; $1.1M boughtOK
- Accounting — Altman-Z distressWatch
Where the revenue comes from
Fiscal 2025, as Alpha Cognition Inc. reports it. History and quarterly detail are in the app.
- Product Net$6.8M
- License$3.4M
- Licensing$598K
Leadership changes
From Alpha Cognition Inc.'s own filings, the day they're filed.
- Bethany Sensenig · director · appointmenteff. 2026-04-15
- Robert Wills · Director · appointmenteff. 2025-04-07
- John Havens · Directors · departureeff. 2025-04-07
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-06-23
- 10-Q · Quarterly report2026-05-14
- DEF 14A · Annual proxy (pay & governance)2026-04-30
- 8-K · Company announcement2026-04-20
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Alpha Cognition Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.